Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: * AZT, ddI, or ddC (provided patient has been on a stable regimen for at least 4 weeks prior to study entry). * Prophylactic aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone (provided patient has been on a stable regimen for at least 4 weeks prior to study entry). Patients must have: * Documented HIV infection or diagnosis of AIDS. * Life expectancy of at least 3 months. Prior Medication: Allowed: * Prior AZT, ddI, or ddC. * Prophylactic aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active, serious infections (other than HIV infections) that require parenteral antibiotic therapy. * Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. * Gastrointestinal malabsorption syndrome or inability to receive oral medication. Concurrent Medication: Excluded: * Diuretics. * Amphotericin B. * Aminoglycoside antibiotics. * Parenteral antibiotics. * Other nephrotoxic agents. * Other investigational agents. * Non-steroidal anti-inflammatory drugs. * Aspirin. Prior Medication: Excluded within 2 weeks prior to study entry: * Diuretics. * Amphotericin B. * Aminoglycoside antibiotics. * Parenteral antibiotics. * Other nephrotoxic agents. * Other investigational agents. Excluded within 3 days prior to study entry: * Non-steroidal anti-inflammatory drugs. * Aspirin. Active substance abuse (including alcohol or drug abuse).